Hidradenitis Suppurativa

Ixekizumab shows promise in restoring clinical response for hidradenitis suppurativa patients previously unresponsive to adalimumab, highlighting new treatment options.

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

In part 3 of this Frontline Forum supplement, experts discuss surgical innovations in HS, setting treatment expectations, and more.

In part 2 of this Frontline Forum supplement, experts discuss current and emerging treatments, digital tools and supports, and more.

In part 1 of this Frontline Forum supplement, experts discuss the burden of HS, reducing diagnostic delays, and more.

Incyte’s phase 3 STOP-HS trials demonstrated significant efficacy and safety of povorcitinib in moderate to severe hidradenitis suppurativa.

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Charrow shares insights in complex dermatology and her work in HS at the annual meeting.

Colleen Cotton, MD, shared clinical tips in treating HS in pediatric patients at the annual SPD Pre-AAD Meeting.

Alexandra P. Charrow, MD, FAAD, shares insights on the link between dermatology and irritable bowel disease at the AAD Annual Meeting.

Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among patients.

A case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, highlighting unique histopathology and complications.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in hidradenitis suppurativa this year.

Hidradenitis suppurativa requires clinical vigilance, empathy, and the courage to escalate therapy early.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.

Panelists discuss how artificial intelligence could revolutionize HS diagnosis through automated image analysis, pattern recognition of clinical presentations, and improved early detection capabilities, potentially reducing diagnostic delays.

Panelists discuss future innovations in hidradenitis suppurativa (HS) treatment and recommendations for guidelines and support groups.

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Panelists discuss how hidradenitis suppurativa significantly impacts patients' quality of life through chronic pain, skin lesions, and social stigma, while remaining frequently misdiagnosed or diagnosed late due to low disease awareness among healthcare providers.

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

Older adults with higher genetic risk for HS show increased risks for coronary artery disease and diabetes, according to UK Biobank data.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

A novel study assessed the potential of 2 AI platforms in providing accurate information to patients with HS.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

A recent analysis found primary closure in HS surgery has higher recurrence rates, while secondary intention healing avoids complications but prolongs recovery.